Rilimogene galvacirepvec-rilimogene glafolivec

Drug Profile

Rilimogene galvacirepvec-rilimogene glafolivec

Alternative Names: PROSTVAC; PROSTVAC-V-PROSTVAC-F; PROSTVAC-VF-TRICOM; PSA-TRICOM; Recombinant vaccinia virus vaccine (PROSTVAC-V/F) - BN ImmunoTherapeutics; Rilimogene gamvacirepvec-rilimogene glafolivec; Vaccinia PSA TRICOM-fowlpox PSA TRICOM

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 16 Jun 2017 Efficacy data from a phase II trial in Prostate cancer released by Bavarian Nordic
  • 08 Jun 2017 National Cancer Institute completes a phase II trial in Prostate cancer (Combination therapy) in USA (SC) (NCT00450463)
  • 19 Apr 2017 Bavarian Nordic initiates a phase II trial in Prostate cancer (Neoadjuvant therapy, Combination therapy) in USA (SC) (NCT02933255)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top